Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?
Rakesh Popat, Ashraf Badros, Shaji Kumar, Paula Rodríguez‐Otero, Adam D. Cohen, Salomon Manier, Peter M. Voorhees, Francesca Gay, Robert M. Rifkin, Thomas G. Martin, Ajai Chari, Katja Weisel, Asim V. Farooq, Bennie H. Jeng, Wee Joo Chng, Hans C. Lee, Jesús G. Berdeja, Vinay Jadhav, Alessandra Tosolini, Laurie Eliason, Antonio Palumbo, Meletios A Dimopoulos, Sagar Lonial, Suzanne Trudel, Paul G. Richardson, Evangelos Terpos (2021). Can Patient-Reported Ocular Symptoms Guide Dose Modifications in Patients with Relapsed/Refractory Multiple Myeloma Receiving Belantamab Mafodotin?. , 138(Supplement 1), DOI: https://doi.org/10.1182/blood-2021-152681.
Article33 days agoSubgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease
Joshua Richter, Jacob P. Laubach, Steve Stricker, Fredrik Schjesvold, David Cohan, Anna Sureda, Ewa Lech‐Marańda, Meral Beksaç, Vânia Hungria, Meletios A Dimopoulos, Ajai Chari, Paul G. Richardson, Philippe Moreau (2021). Subgroup Analysis: Efficacy and Safety of Panobinostat in Combination with SC Bortezomib and Oral Dexamethasone in Multiple Myeloma Patients with Lenalidomide-Refractory Disease. , 138(Supplement 1), DOI: https://doi.org/10.1182/blood-2021-153694.
Article33 days agoP-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma
Ajai Chari, Meletios A Dimopoulos, Meral Beksaç, Xavier Leleu, Katja Weisel, Joshua Richter, Franziska Dirnberger, Karim Iskander, Akeem Yusuf, Joseph Mıkhael (2021). P-191: Comparison of efficacy outcomes for Carfilzomib plus Dexamethasone and Daratumumab (KdD) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) and D-Pd in relapsed or refractory Multiple Myeloma. , 21, DOI: https://doi.org/10.1016/s2152-2650(21)02318-1.
Article33 days agoSelinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk
Shambavi Richard, Ajai Chari, Sosana Delimpasi, Maryana Simonova, Ivan Špıčka, Luděk Pour, Iryna Kriachok, Meletios A Dimopoulos, Halyna Pylypenko, Holger W. Auner, Xavier Leleu, Ganna Usenko, Roman Hájek, Reuben Benjamin, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Christopher P. Venner, Mamta Garg, Don A. Stevens, Hang Quach, Sundar Jagannath, Philippe Moreau, Moshe Levy, Ashraf Badros, Larry D. Anderson, Nizar J. Bahlis, Thierry Façon, María‐Victoria Mateos, Michèle Cavo, Hua Chang, Yosef Landesman, Yi Chai, Melina Arazy, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Sebastian Grosicki, Paul G. Richardson (2021). Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. , 96(9), DOI: https://doi.org/10.1002/ajh.26261.
Article33 days agoIntegrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials
Maria Gavriatopoulou, Ajai Chari, Christine Chen, Nizar J. Bahlis, Dan T. Vogl, Andrzej Jakubowiak, David Dingli, Robert F. Cornell, Craig C. Hofmeister, David S. Siegel, Jesús G. Berdeja, Donna Reece, Darrell White, Suzanne Lentzsch, Cristina Gasparetto, Carol Ann Huff, Sundar Jagannath, Rachid Baz, Ajay K. Nooka, Joshua Richter, Rafat Abonour, Terri L. Parker, Andrew J. Yee, Philippe Moreau, Sagar Lonial, Sascha A. Tuchman, Katja Weisel, Mohamad Mohty, Sylvain Choquet, Thaddeus J. Unger, Kwok Yan Li, Yi Chai, Lingling Li, Jatin J. Shah, Sharon Shacham, Michael Kauffman, Meletios A Dimopoulos (2020). Integrated safety profile of selinexor in multiple myeloma: experience from 437 patients enrolled in clinical trials. , 34(9), DOI: https://doi.org/10.1038/s41375-020-0756-6.
Article33 days ago